Education
About Us
Working with TipRanks
Follow Us
Enzo Biochem (ENZ)
NYSE:ENZ
Top Page
Enzo Biochem
(NYSE:ENZ)
45Neutral
Enzo Biochem (ENZ) vs. S&P 500 (SPY)
Market Cap
$22.60M
Dividend YieldN/A
Average Volume (3M)106.53K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees125
SectorHealthcare
Sector Strength71
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.41
Shares Outstanding52,402,805
10 Day Avg. Volume108,071
30 Day Avg. Volume106,525
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.88
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Enzo Biochem Business Overview & Revenue Model
Company DescriptionEnzo Biochem, Inc. (ENZ) is a life sciences and biotechnology company that operates in the fields of research, development, and clinical diagnostics. The company is engaged in the development of innovative solutions for the global healthcare market, focusing on the manufacture and distribution of diagnostic products, tools, and services. Enzo Biochem operates through two main segments: Enzo Clinical Labs, which provides a wide range of routine and esoteric testing services, and Enzo Life Sciences, which develops, manufactures, and markets reagents, kits, and other products for clinical research and drug development.
How the Company Makes MoneyEnzo Biochem generates revenue primarily through its two operational segments. The Enzo Clinical Labs segment earns income by providing diagnostic testing services to physicians, medical centers, and other healthcare facilities. This segment is a key revenue driver due to the high volume of tests it conducts, which includes both routine and specialized testing services. The Enzo Life Sciences segment, on the other hand, generates revenue through the sale of life science research products and tools that include antibodies, proteins, assays, and small molecules. This segment caters to a global market of academic and government institutions, biotechnology and pharmaceutical companies. Enzo Biochem's revenue model is supported by its proprietary technologies and strategic partnerships, which enhance its capabilities in product development and distribution.
Enzo Biochem Financial Statement Overview
Summary
Enzo Biochem demonstrates a challenging financial situation, with declining revenues, profitability, and cash flows. Although the balance sheet shows moderate leverage, the company faces significant operational and cash flow challenges. Strategic improvements are essential to stabilize and enhance financial performance.Income Statement
Enzo Biochem has experienced significant revenue declines from its peak in 2021. The trailing twelve months (TTM) data shows a negative net profit margin and declining gross profit margin, indicating challenges in maintaining profitability. The company has negative EBIT and EBITDA margins, reflecting operational inefficiencies.45
Neutral
Balance Sheet
The company maintains a moderate debt-to-equity ratio, suggesting manageable leverage levels. However, declining stockholders' equity and total assets highlight potential risks. The positive equity ratio indicates a solid capital structure, but diminishing asset base raises concerns.60
Neutral
Cash Flow
Operating cash flow remains negative, indicating cash flow challenges. Free cash flow has also been consistently negative, demonstrating cash generation issues. The company needs to improve its cash flow management to support operations and growth.50
Neutral
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 29.09M | 31.91M | 31.06M | 107.07M | 117.73M | 76.02M | Gross Profit |
| 13.27M | 14.63M | 11.57M | 41.97M | 53.58M | 23.77M | EBIT |
| -8.34M | -9.82M | -24.74M | -15.51M | 9.88M | -23.64M | EBITDA |
| -7.33M | -8.35M | -20.94M | -15.01M | 3.35M | -27.59M | Net Income Common Stockholders |
| -21.31M | -26.08M | 20.29M | -22.58M | 3.42M | -33.89M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 40.30M | 52.37M | 82.37M | 21.60M | 43.50M | 47.87M | Total Assets |
| 67.51M | 85.76M | 121.88M | 95.86M | 113.69M | 112.54M | Total Debt |
| 2.92M | 3.51M | 7.00M | 20.59M | 22.68M | 32.79M | Net Debt |
| -37.38M | -48.86M | -75.38M | -1.02M | 9.15M | -15.07M | Total Liabilities |
| 20.89M | 29.65M | 43.42M | 41.40M | 45.10M | 54.16M | Stockholders Equity |
| 46.62M | 56.11M | 78.46M | 54.46M | 68.59M | 58.38M |
| Cash Flow | Free Cash Flow | ||||
| -15.75M | -26.80M | -39.74M | -20.06M | -4.05M | -19.35M | Operating Cash Flow |
| -14.96M | -26.26M | -36.98M | -16.59M | 387.00K | -17.18M | Investing Cash Flow |
| 4.22M | -545.00K | 98.98M | 25.22M | -34.50M | -2.17M | Financing Cash Flow |
| -9.18M | -4.19M | -1.13M | -241.00K | -242.00K | 7.00M |
Enzo Biochem Technical Analysis
Negative
0.43
Price Trends
0.53
Negative
0.72
Negative
0.87
Negative
Market Momentum
-0.02
Negative
33.12
Neutral
8.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZ, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.53, and below the 200-day MA of 0.87, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 33.12 is Neutral, neither overbought nor oversold. The STOCH value of 8.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENZ.
Enzo Biochem Risk Analysis
Enzo Biochem disclosed 30 risk factors in its most recent earnings report. Enzo Biochem reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enzo Biochem Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $995.45M | 17.66 | 19.46% | ― | 19.07% | ― | |
52 Neutral | $256.56M | 25.27 | -4.64% | ― | -54.17% | -135.78% | |
51 Neutral | $810.82M | ― | -17.15% | ― | 12.15% | 61.33% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 19.94% | 1.20% | |
46 Neutral | $2.35B | ― | -50.74% | ― | -7.03% | -20233.78% | |
45 Neutral | $22.60M | ― | -12.94% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
ENZ
Enzo Biochem
0.43
-0.71
-62.28%
MYGN
Myriad Genetics
8.88
-12.56
-58.58%
OSUR
Orasure Technologies
3.43
-2.65
-43.59%
QDEL
QuidelOrtho
34.89
-12.11
-25.77%
CDNA
CareDx
17.96
7.64
74.03%
Enzo Biochem Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Enzo Biochem Faces NYSE Compliance Challenges
Negative
Jan 14, 2025
On January 8, 2025, Enzo Biochem, Inc. received a notice of non-compliance from the New York Stock Exchange, as its market capitalization and stockholder’s equity fell below $50 million, and its average stock price was under $1.00 for 30 consecutive trading days. The company has 18 months to address the capitalization and equity issues and six months to resolve the stock price deficiency, during which its stock will continue trading on the NYSE. Enzo Biochem plans to submit a corrective plan by February 21, 2025, and is considering various alternatives to regain compliance, ensuring its continued listing on the exchange while maintaining adherence to other NYSE standards.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.